Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short Interest

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 12,530,000 shares, a drop of 6.4% from the August 31st total of 13,390,000 shares. Based on an average daily volume of 2,170,000 shares, the short-interest ratio is currently 5.8 days.

Analysts Set New Price Targets

Separately, EF Hutton Acquisition Co. I upgraded shares of Citius Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 15th.

Citius Pharmaceuticals Price Performance

Shares of CTXR opened at $0.52 on Monday. The firm has a fifty day moving average price of $0.67 and a 200 day moving average price of $0.70. The stock has a market cap of $94.29 million, a PE ratio of -2.17 and a beta of 1.60. Citius Pharmaceuticals has a 1-year low of $0.48 and a 1-year high of $1.07.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). As a group, equities analysts expect that Citius Pharmaceuticals will post -0.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Citius Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Citius Pharmaceuticals in the second quarter valued at approximately $29,000. Arkadios Wealth Advisors boosted its stake in shares of Citius Pharmaceuticals by 50.0% in the second quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock valued at $88,000 after buying an additional 50,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in Citius Pharmaceuticals by 1.5% during the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after acquiring an additional 104,889 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Citius Pharmaceuticals in the second quarter worth $69,000. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.